glp 1 is retatrutide Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Retatrutide 10mg & 20mg Research

Adverse effects appear to be rare, and this peptide definitely warrants further human studies to evaluate its effects

Women aged 5064 had the highest use overall, with 20 percent reporting current or past GLP-1 use

[13] [14] BPC-157 has been widely used both by athletes and among the general public, mainly for recovery from injury or stimulating healing in chronic conditions, [15] [12] [16] [17] but there is as yet only very limited human trial data on efficacy and only a few preliminary safety studies

Discuss your current medications with your nurse during intake so the right approach can be confirmed for your specific situation

Deshalb wird Cagrilintide in erster Linie als Partner der GLP-1-Agonisten und nicht als deren Ersatz untersucht